From 6 to 8 October, we exhibited at BiotechX Europe in Basel. Across three days of sessions and booth conversations, one topic kept coming back: data. Not how much of it exists, but who it represents and how it can be brought together.

At our booth: from ambition to practice

We welcomed pharma and biotech leaders, R&D and data science teams, and academic researchers at our booth for live demos of PaiX Navigator, info sessions and one-to-one meetings.

The questions went straight to practice. Where does representative data actually come from? How do you bring together records from different countries, coding systems and languages without flattening the differences between populations that make it valuable? And once it is harmonized, how do you know an answer can be trusted? PaiX Navigator is built around these questions: researchers and clinicians ask in plain language, test whether a finding holds across populations, and trace every chart and table back to the query that produced it.

On stage: quality is not the same as coverage

Sessions on trustworthy AI made a strong case for FAIR data: findable, accessible, interoperable and reusable. They also showed where that framework stops. FAIR describes how data is managed, not who it covers. A perfectly curated dataset can still leave out most of the world. With around 84% of the global population underrepresented in the data health AI learns from, coverage is becoming as important as quality. Regulation points the same way: the EU AI Act requires data for high-risk AI to be sufficiently representative, not only well managed.

Sessions on agentic AI raised the stakes further. When AI systems act across R&D pipelines, they make decisions in sequence. A gap in the data does not stay in one analysis. It carries into every step that follows. The more autonomy we give AI, the more its data foundation matters.

What we take home

Basel confirmed what we see in our own work: representative data is becoming an industry priority, and harmonization is where it will succeed or fail. Data from diverse countries is only the first step. Making it comparable, while keeping the signals that differ between populations, is what turns diversity into evidence. That is why we are integrating harmonized data from partners in more than 60 countries into PaiX Navigator, so the same question can be tested beyond European cohorts.

Thank you to everyone who visited our booth, and to our team in Basel, Dr. Jubin Shah, Dr. John Wong and Gizem Yazli, for three days of great conversations. If we did not get to meet at BiotechX, request early access to explore PaiX Navigator.